Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
MFN pricing and TrumpRx do not directly impact employer plan coverage
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Long-term safety data are still being collected in ongoing Phase 3 trials
Maximum benefits including sustained high-quality sleep and long-term sleep wellness often manifest over 4-12 weeks of consistent therapy
Contaminated peptides can cause injection site infections, systemic immune reactions, fever, and other adverse effects
Adipose tissue, particularly visceral fat, produces elevated levels of pro-inflammatory cytokines including IL-6, TNF-alpha, and thymic stromal lymphopoietin (TSLP), all of which drive the type 2 inflammatory response underlying atopic dermatitis
